ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2021
Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00835289 (The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial), which is not on this map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- The effects of various nutritional supplements in patients with chronic obstructive pulmonary disease: a network meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Comparative Efficacy of Nutritional Supplements in Modulating Lung Function and Exercise Capacity in COPD Patients: A Network Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Pooled it
- Effect of Omega-3 Fatty Acids on Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.International journal of chronic obstructive pulmonary diseasePooled it
- The Inflammatory Roles of n-3 and n-6 Polyunsaturated Fatty Acids in COPD: Clinical Implications and Underlying Mechanisms.Journal of inflammation research · 2026Review
- Omega-3 Fatty Acids and Chronic Lung Diseases: A Narrative Review of Impacts from Womb to Tomb.The Journal of nutrition · 2025Review
- Natural Products for the Management of Asthma and COPD.Handbook of experimental pharmacology · 2025Review
- Association between polyunsaturated fatty acids dietary intake and pulmonary function among American children: NHANES 2007-2012.Frontiers in nutrition · 2025Article
- Article
- The Possible Role of Food and Diet in the Quality of Life in Patients with COPD-A State-of-the-Art Review.Nutrients · 2023Review
- The Effectiveness of Supplementation with Key Vitamins, Minerals, Antioxidants and Specific Nutritional Supplements in COPD-A Review.Nutrients · 2023Review
- Inflammation resolution in environmental pulmonary health and morbidity.Toxicology and applied pharmacology · 2022Review
- The Dietary Inflammatory Index and Early COPD: Results from the National Health and Nutrition Examination Survey.Nutrients · 2022Article
- Chronic Obstructive Pulmonary Disease: Is Social Injustice the Elephant in the Room?American journal of respiratory and critical care medicine · 2021Article
- Letter to the Editor: Response by Authors.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2021Article
- Omega-3 Fatty Acid Supplementation for Endothelial Dysfunction in COPD: Another Fiasco? Or Maybe Not?Chronic obstructive pulmonary diseases (Miami, Fla.) · 2021Article
- Fish oil supplementation in chronic obstructive pulmonary disease: feasibility of conducting a randomised controlled trial.Pilot and feasibility studies · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleStudies suggest a pathogenic role of endothelial dysfunction in chronic obstructive lung disease (COPD). Omega-3 (n-3) polyunsaturated fatty acid (PUFA) supplementation improves endothelial function in other diseases but has not been examined in COPD.
objectiveWe hypothesized that n-3 PUFA supplementation would improve systemic endothelial function in COPD. We performed a pilot randomized, placebo-controlled, double-blind, phase 2 superiority trial (NCT00835289).
methodsAdults with moderate and severe stable COPD (79% with emphysema on computed tomography [CT]) were randomized to high-dose fish oil capsules or placebo daily for 6 months. The primary endpoint was percentage change in brachial artery flow-mediated dilation (FMD) from baseline to 6 months. Secondary endpoints included peripheral arterial tonometry, endothelial microparticles (EMPs), 6-minute walk distance, respiratory symptoms, and pulmonary function.
resultsThirty-three of 40 randomized participants completed all measurements. Change in FMD after 6 months did not differ between the fish oil and placebo arms (-1.1%, 95% CI -5.0-2.9,
conclusionRandomization to n-3 PUFAs for 6 months did not change systemic endothelial function in COPD. Changes in EMPs and SGRQ suggest n-3 PUFAs might have biologic and clinical effects that warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.